
Join to View Full Profile
11535 Sorrento Valley Road #400San Diego, CA 92121
Dr. Das is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a medical oncologist (formerly at Vanderbilt-Ingram Cancer Center) with a background in gastrointestinal cancer, neuroendocrine cancer and phase I, now a drug developer in industry. Some of the therapeutic classes I have worked on include antibody-drug conjugates, radioligand therapies, DNA damage repair inhibitors, targeted protein degraders and immunotherapy. I have experience, from time in academia, large biopharma and biotech, in both early- & late-phase clinical development.
Education & Training
- Vanderbilt University MSCI, Clinical Investigation , 2018 - 2020
- Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2016 - 2018
- University of California (San Diego) Medical CenterResidency, Internal Medicine, 2013 - 2016
- Emory University School of MedicineClass of 2013
- University of California, BerkeleyBA, Molecular Cell Biology, 2004 - 2008
Certifications & Licensure
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
- Cornell University Pharmaceutical Management Foundations
Awards, Honors, & Recognition
- Patient Experience Award Vanderbilt University Medical Center, 2020-2022
- NCI NET Task Force Junior Member National Cancer Institute
- NCCN Neuroendocrine and Adrenal Tumors Guidelines Panel NCCN
- Join now to see all
Clinical Trials
- A Study of Peluntamig (PT217) in Patients with Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) Start of enrollment: 2023 Sep 05
- Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) Start of enrollment: 2023 Mar 15
- Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) Start of enrollment: 2022 Aug 11
Publications & Presentations
PubMed
- Systemic Therapy Improvements Will Render Locoregional Treatments Obsolete for Patients with Cancer with Liver Metastases.Satya Das, Jordan Berlin
Hematology/oncology Clinics of North America. 2025-02-01 - Predictions.Satya Das
JAMA Oncology. 2024-07-01 - Evolving or immutable - phase I solid tumor trials in the era of precision oncology.Shannon S Stockton, G Dan Ayers, Cody Lee, Heather Laferriere, Satya Das
Investigational New Drugs. 2024-06-01
Journal Articles
- Harnessing the Immune System in Pancreatic CancerSatya Das, Jordan Berlin, Dana Cardin, Current Treatment Opinions in Oncology, 8/13/2018
- Hidden Figures: Occult Intra-Cardiac Metastases in Asymptomatic Neuroendocrine Tumor PatientsSatya Das, Gino Pineda, Jordan Berlin, Brian Hemphill, Javid Moslehi, Anju Nohria, George Fisher, Journal of Oncology and Cancer Research, 7/26/2018
- Quality Matters: Immunotherapy and the Evolving Landscape of Advanced Cancer CareDas S, Horn L, Expert Review of Quality of Life in Cancer Care, 1/1/2017
- Join now to see all
Abstracts/Posters
- A phase II study of M6620 and irinotecan in TP53 mutant gastric and gastroesophageal junction (GEJ) adenocarcinoma patients (pts) [NCT03641313].Satya Das, Jennifer Whisenant, Austin Doyle, Carmen Joseph Allegra, Jordan Berlin, GI ASCO, San Francisco, 1/2019
- Peritoneal carcinomatosis (PC) in well-differentiated (WD) small-intestinal neuroendocrine tumor (SI-NET) patients (Pts) with mesenteric tumor deposits (MTDs)Satya Das, Chanjuan Shi, Tatsuki Koyama, Yi Huang, Raul S. Gonzalez, Kamran Idrees, Christina Edwards Bailey, Jordan Berlin, GI ASCO, 1/2019
- Peritoneal carcinomatosis (PC) in well differentiated small intestinal neuroendocrine tumors (SI-NET)Satya Das, Chanjuan Shi, Tatsuki Koyama, Jordan Berlin, ASCO, Chicago, 6/2018
- Join now to see all
Lectures
- A phase II study of enterade in neuroendocrine tumor (NET) patients with quality-of-life limiting bowel movement frequency.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Neuroendocrine Tumors: An Overview2019 NCAN Tennessee NET Patient Conference - 9/14/2019
- The Role for Cell Free Circulating DNA in Detecting Secondary EGFR Mutations in Advanced Stage Non-Small Cell Lung Cancer PatientsSan Diego, CA - 1/1/2015
Authored Content
- A Career in Clinical Development in Industry: Choose Your Own AdventureMarch 2025
Press Mentions
- Targeted Therapy for Neuroendocrine TumorsFebruary 16th, 2023
- Shifts in Neuroendocrine Cancer Clinical Trial DesignNovember 2nd, 2021
- Calithera Biosciences Announces CB-839 Abstracts Accepted for Presentation at ASCO 2018April 25th, 2018
- Join now to see all
Professional Memberships
- Member
- Member
External Links
- Linkedinhttp://www.linkedin.com/in/satya-nanu-das-md-msci-755177243
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: